secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001104659-23-076346
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD
--------------------------------------------------------------------------------

- Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.
- Clinical benefit rate 75% and disease control rate 85.7% at >60 mCi TAD.
- Triple-class refractory patients achieved 46% ORR (median PFS 3.4 mo); quad-class 50% ORR.
- Grade 3/4 cytopenias common (62.5% thrombocytopenia, anemia, neutropenia); no off-target toxicities.
- Drug given as four 15-min IV infusions over 3 months with low-dose dexamethasone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/0001104659-23-076346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/tm2320208d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-076346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer